We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug
Read MoreHide Full Article
Shares of Feneca Pharmaceuticals (FENC - Free Report) were up almost 12% on Sep 21, after the company announced that the FDA approved its only product candidate Pedmark (sodium thiosulfate injection).
The FDA has approved Pedmark to reduce the risk of hearing loss or ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors.
Cisplatin is a critical chemotherapeutic agent used to treat pediatric malignancies. However, even though effective, this platinum-based therapy can harm children, causing permanent and irreversible bilateral hearing loss.
With Pedmark’s approval, physicians now have an approved treatment option to reduce the risk of cisplatin-induced hearing loss in pediatric patients.
Pedmark is currently the only treatment approved by the FDA for the indications above, an area of significant unmet medical need.
The regulatory clearance is expected to significantly solidify Feneca’s portfolio, thereby contributing to its revenue generation in the near term.
Feneca Pharmaceuticals’ shares have surged 94.1% in the year-to-date period against the industry’s decline of 25%.
Image Source: Zacks Investment Research
The FDA approval for Pedmark was based on the safety and efficacy data from two randomized phase III studies, SIOPEL 6 and COG ACCL0431, which evaluated Pedmark in pediatric patients undergoing treatment with cisplatin-based chemotherapy for their cancer. In the studies, Pedmark consistently and significantly reduced the incidence of hearing loss in the subjects.
Feneca completed the submission of its new drug application (NDA) for Pedmark in February 2020. However, in August 2020, the company received a complete response letter (CRL) against its NDA for Pedmark for intravenous administration to prevent ototoxicity associated with cisplatin chemotherapy in pediatric patients with localized, non-metastatic, solid tumors.
The CRL was issued to indicate that the regulatory body completed its pre-approval inspection and identified deficiencies with the facility of the drug product manufacturer, which required to be resolved before Pedmark was approved. No clinical safety or efficacy issues with Pedmark were identified and no further clinical data was required to be submitted.
Following the receipt of final minutes from a Type A NDA meeting with the FDA, Feneca resubmitted its NDA for Pedmark in May 2021, which was accepted by the FDA a month later in June.
However, the company received a second CRL in November 2021 after the FDA again identified manufacturing deficiencies.
The NDA for Pedmark was accepted by the FDA in April 2022. Pedmark received both Breakthrough Therapy and Fast Track Designation by the FDA.
Feneca also submitted a marketing authorization application (MAA) for sodium thiosulfate, to be marketed in Europe by the trade name Pedmarqsi, to the European Medicines Agency (EMA). The MAA for sodium thiosulfate is currently under evaluation by the EMA.
Acer Therapeutics’ loss per share estimates for 2022 have improved from $3.23 to $2.47 in the past 30 days. The same for 2023 has improved from $1.44 to $1.07 in the same time frame.
Earnings of Acer missed estimates in two of the trailing four quarters and beat the same on the remaining two occasions. The average negative earnings surprise for ACER is 106.16%.
Aerie Therapeutics’ loss per share estimates for 2022 have improved from $3.47 to $2.47 in the past 30 days. The same for 2023 has improved from $1.49 to $1.07 in the same time frame.
Earnings of Aerie beat estimates in three of the trailing four quarters and missed the same in the remaining occasion. The average earnings surprise for AERI is 70.27%.
Soleno Therapeutics’ loss per share estimates for 2022 remained steady at $4.05 over the past 30 days. The same for 2023 has remained steady at $2.10 in the same time frame.
Earnings of Soleno missed estimates in three of the trailing four quarters and were in line on the remaining occasion. The average earnings surprise for SLNO is 11.40%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug
Shares of Feneca Pharmaceuticals (FENC - Free Report) were up almost 12% on Sep 21, after the company announced that the FDA approved its only product candidate Pedmark (sodium thiosulfate injection).
The FDA has approved Pedmark to reduce the risk of hearing loss or ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors.
Cisplatin is a critical chemotherapeutic agent used to treat pediatric malignancies. However, even though effective, this platinum-based therapy can harm children, causing permanent and irreversible bilateral hearing loss.
With Pedmark’s approval, physicians now have an approved treatment option to reduce the risk of cisplatin-induced hearing loss in pediatric patients.
Pedmark is currently the only treatment approved by the FDA for the indications above, an area of significant unmet medical need.
The regulatory clearance is expected to significantly solidify Feneca’s portfolio, thereby contributing to its revenue generation in the near term.
Feneca Pharmaceuticals’ shares have surged 94.1% in the year-to-date period against the industry’s decline of 25%.
Image Source: Zacks Investment Research
The FDA approval for Pedmark was based on the safety and efficacy data from two randomized phase III studies, SIOPEL 6 and COG ACCL0431, which evaluated Pedmark in pediatric patients undergoing treatment with cisplatin-based chemotherapy for their cancer. In the studies, Pedmark consistently and significantly reduced the incidence of hearing loss in the subjects.
Feneca completed the submission of its new drug application (NDA) for Pedmark in February 2020. However, in August 2020, the company received a complete response letter (CRL) against its NDA for Pedmark for intravenous administration to prevent ototoxicity associated with cisplatin chemotherapy in pediatric patients with localized, non-metastatic, solid tumors.
The CRL was issued to indicate that the regulatory body completed its pre-approval inspection and identified deficiencies with the facility of the drug product manufacturer, which required to be resolved before Pedmark was approved. No clinical safety or efficacy issues with Pedmark were identified and no further clinical data was required to be submitted.
Following the receipt of final minutes from a Type A NDA meeting with the FDA, Feneca resubmitted its NDA for Pedmark in May 2021, which was accepted by the FDA a month later in June.
However, the company received a second CRL in November 2021 after the FDA again identified manufacturing deficiencies.
The NDA for Pedmark was accepted by the FDA in April 2022. Pedmark received both Breakthrough Therapy and Fast Track Designation by the FDA.
Feneca also submitted a marketing authorization application (MAA) for sodium thiosulfate, to be marketed in Europe by the trade name Pedmarqsi, to the European Medicines Agency (EMA). The MAA for sodium thiosulfate is currently under evaluation by the EMA.
Zacks Rank and Stocks to Consider
Feneca currently has a Zacks Rank #4 (Buy).
Some better-ranked stock in the same sector is Acer Therapeutics (ACER - Free Report) , Aerie Pharmaceuticals and Soleno Therapeutics (SLNO - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Acer Therapeutics’ loss per share estimates for 2022 have improved from $3.23 to $2.47 in the past 30 days. The same for 2023 has improved from $1.44 to $1.07 in the same time frame.
Earnings of Acer missed estimates in two of the trailing four quarters and beat the same on the remaining two occasions. The average negative earnings surprise for ACER is 106.16%.
Aerie Therapeutics’ loss per share estimates for 2022 have improved from $3.47 to $2.47 in the past 30 days. The same for 2023 has improved from $1.49 to $1.07 in the same time frame.
Earnings of Aerie beat estimates in three of the trailing four quarters and missed the same in the remaining occasion. The average earnings surprise for AERI is 70.27%.
Soleno Therapeutics’ loss per share estimates for 2022 remained steady at $4.05 over the past 30 days. The same for 2023 has remained steady at $2.10 in the same time frame.
Earnings of Soleno missed estimates in three of the trailing four quarters and were in line on the remaining occasion. The average earnings surprise for SLNO is 11.40%.